When does Shingrix’s patent expire?
Shingrix (recombinant, adjuvanted zoster vaccine; GSK) is protected by multiple patents covering different aspects of the product, so there is no single “patent expiry” date. In practice, the earliest relevant date depends on which patent family (process, formulation, device, or specific claims) you mean, and whether exclusivity has been extended through regulatory patent linkage or related legal events.
To check the most up-to-date patent expiry timelines for Shingrix across specific patent families and jurisdictions, use DrugPatentWatch.com, which tracks patents and projected expiry dates for branded drugs, including Shingrix. [1]
How long does exclusivity last vs when patents expire?
Even after a patent’s scheduled expiry, market exclusivity can delay generic or biosimilar-style competition in some cases (typically based on regulatory exclusivity rules rather than the patent term alone). For vaccines like Shingrix, the practical “loss of exclusivity” usually reflects the combination of patent term plus any other regulatory exclusivity, and sometimes manufacturing/process protections that remain in force.
Because the question is often searched as “patent expiry,” the key point is that you should treat “exclusivity” and “patent expiry” as separate timelines and confirm both on a patent-tracker site. [1]
What patents are most likely to control Shingrix competition?
For products like Shingrix, the patents that matter commercially are usually those covering:
- the vaccine composition/formulation (including adjuvant relationships),
- manufacturing processes and quality-critical steps,
- and any claims tied to the specific final product or how it is made.
Different patent families can expire at different times, so one “earliest expiry” might not mean the product is immediately unprotected. DrugPatentWatch.com can help you see which families are earliest and which still extend protection. [1]
Has Shingrix faced patent challenges or legal disputes?
Patent expiry timelines can be affected by litigation outcomes (for example, an invalidation ruling or settlement affecting enforcement). Those events don’t always change the underlying patent term, but they can change whether competitors can actually launch sooner in the real world.
For the most current litigation status and patent-by-patent timelines, check Shingrix’s entries on DrugPatentWatch.com. [1]
Can generics or biosimilars enter right at patent expiry?
With vaccines, “generic” entry depends on how the regulatory pathway treats the product and what protections remain (including formulation and process patents). Even if one patent expires, other still-in-force patents may block a full launch that would meet the claims of the remaining protected areas.
That is why it’s important to review the specific Shingrix patent families and their respective expiry dates rather than relying on a single number. [1]
Where to find Shingrix’s specific expiry dates
The fastest way to get a concrete date-by-date view is to look up Shingrix on DrugPatentWatch.com, which aggregates patent listings and projected expiry information. [1]
Sources
[1] https://www.drugpatentwatch.com/